David Cattaneo’s Post

Discovering IL-17’s expansive therapeutic frontiers! A new review in Signal Transduction and Targeted Therapy illuminates the vast medical potential of the IL-17 pathway, a key area of interest for us at Pepticom in our journey of AI-driven drug discovery. Recommend a read >> https://lnkd.in/decNerUt The article covers IL-17's pivotal role in a range of biological functions, from influencing inflammatory responses in autoimmune diseases to bolstering immunity against various pathogens. Its significance extends to tissue repair, inflammatory disease pathogenesis, and roles in cancer progression and treatment. The review particularly highlights IL-17’s mechanisms in skin inflammation, especially in psoriasis, and delves into its roles in other conditions like inflammatory bowel disease, Systemic lupus erythematosus (SLE), and more. As a target for drug development, it is proving to be a highly exciting and expanding field of research holding much potential promise. In the field of psoriasis, the review specifically examines some of the recent biologic treatments for conditions like psoriasis—such as secukinumab, ixekizumab, and brodalumab which have improved treatment for difficult to treat psoriatic patients. Though these drugs have provided efficacy advancements, they remain limited by cost and administration challenges, as they usually involve injections that can create a barrier for many patients. This is exactly where our work at Pepticom comes in. We are developing the world’s first AI-designed therapeutic peptidomimetic targeting the IL-17 pathway for psoriasis treatment that offers a potential oral alternative to expensive injectable biologics making treatment more accessible. This review clearly highlights the immense promise of IL-17 in diverse medical applications with the amount of research in this field constantly expanding. With IL-17's role in psoriasis one of our first Pepticom projects, I am excited to see how we can apply this knowledge and expertise to other IL-17 medical areas. If you're attending #JPM2024 next month and are interested in learning more of the potential of AI in drug discovery, please join us at the Health Innovation lounge - https://lnkd.in/dMdwv6Qf or DM Maayan Elias Robicsek or Sarah Benson-Konforty, MD to set-up a meeting! #Peptides #AI #DrugDiscovery #Psoriasis

Shareable Insights by Citeline | Week 30/2024, Part 1 Medtech Insight Sinaptica On Precision Neuromodulation To Combat Alzheimer’s: ‘No Drug Dares Go After Moderate Patients’ https://lnkd.in/eN9p833f •Who should read this? Medical device and pharma executives in R&D, business development, competitor intelligence, specifically at companies treating or targeting Alzheimer’s disease. Also consultants watching this space. •What is it? An interview with Sinaptica Therapeutics CEO Ken Mariash and scientific co-founder Giacomo Koch on the company’s developing precision neuromodulation therapy, an FDA-designated “Breakthrough Device” that has shown impressive results in Phase 2 studies and is headed for a Phase 3 in 2025. •Why is it important? Sinaptica believes its therapy could succeed in Alzheimer’s patients where drugs have failed to slow cognitive decline, even in moderate cases. At the same time, it suspects that combining its approach with anti-amyloid drugs could be “a very synergistic possibility.” This article also provides insight into the US FDA’s TAP program to speed patient access to innovative medical devices, as well as Sinaptica’s machine learning capabilities, both subjects of broad interest. It’s an example of the interviews Medtech Insight is increasingly committed to doing to build our industry networks and provide readers with insider perspectives on key challenges and opportunities in the sector.  

🌟 Exciting News from the Frontier of AI-Driven Drug Discovery! 🌟 🥼🔬 We're thrilled to share a monumental leap in medical science: the first AI-designed drug targeting idiopathic pulmonary fibrosis (IPF) has shown promise in both preclinical and phase I clinical trials. 🚀 🧬 Paper Title: "A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models" 🤖 Using groundbreaking AI technology, researchers identified TRAF2- and NCK-interacting kinase (TNIK) as a key anti-fibrotic target. The AI-designed small molecule, INS018_055, is not just a scientific marvel—it's a beacon of hope for those affected by fibrosis. 💊 INS018_055 has demonstrated impressive anti-fibrotic activity in various organs and boasts an anti-inflammatory profile. This potential game-changer has successfully completed a randomized, double-blinded, placebo-controlled phase I clinical trial, confirming its safety and tolerability. 🕒 What's even more remarkable? This entire process, from target discovery to preclinical candidate nomination, was completed in about 18 months—showcasing the sheer speed and efficiency of AI-driven drug discovery. 🧪 The results are not just a win for IPF treatment but also a testament to the power of AI in revolutionizing the future of medicine. 🌐 Stay tuned as we embark on phase II trials, bringing us closer to a new era of healthcare where AI and human ingenuity converge to combat chronic diseases. https://lnkd.in/d5G_4fpi #AIDrugDiscovery #MedicalInnovation #IPFTreatment #HealthcareRevolution #INS018_055

Omics-Based Clinical Trials Market Report 2022 | By Key Players | Regions | Competitive landscape and Forecast Till 2028 !! 𝐎𝐦𝐢𝐜𝐬-𝐁𝐚𝐬𝐞𝐝 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies), By Indication (Oncology, Cardiology, Respiratory Diseases, Skin Diseases, CNS Diseases, Immunology, Genetic Diseases (includes the rare diseases), Others (includes ophthalmic, ear diseases, etc)) , COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028. Global Omics-Based Clinical Trials Market size was valued at USD 28.3 Billion in 2021 and is projected to reach USD 49.6 Billion by 2028, growing at a CAGR of 7.6% from 2021 to 2028 according to a new report by 𝐈𝐧𝐭𝐞𝐥𝐥𝐞𝐜𝐭𝐮𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡. 𝐘𝐨𝐮 𝐜𝐚𝐧 𝐜𝐡𝐞𝐜𝐤 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:⬇ https://lnkd.in/dAxvDWGX 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐖𝐨𝐫𝐤𝐢𝐧𝐠 𝐈𝐧 𝐓𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭:⬇ Charles River Laboratories Complete Omics Inc. Covance Danaher Corporation Eli Lilly and Company ICON plc Labcorp Merck Group Mission Bio NeoGenomics Laboratories Novo Nordisk Pfizer Rebus Biosystems Thermo Fisher Scientific

🚨 5 approvals in the last 6 months! Updated graphic below reflects the two new FDA approvals achieved on Friday by Vertex Pharmaceuticals/CRISPR Therapeutics and bluebird bio in sickle cell disease. From 32 to now 34 approvals since our last post. 𝘏𝘦𝘳𝘦'𝘴 𝘵𝘩𝘦 𝘤𝘶𝘳𝘳𝘦𝘯𝘵 34 𝘢𝘱𝘱𝘳𝘰𝘷𝘢𝘭 𝘣𝘳𝘦𝘢𝘬𝘥𝘰𝘸𝘯 𝘣𝘺 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘢𝘳𝘦𝘢 👇 𝐇𝐚𝐞𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲 (20 products): - 2 for the treatment of multiple myeloma - 4 for the treatment of lymphoma - 2 for haemophilia - 10 for cell transplant-based therapies - 2 recently approvals for sickle cell disease: 𝐂𝐀𝐒𝐆𝐄𝐕𝐘 and 𝐋𝐘𝐅𝐆𝐄𝐍𝐈𝐀. 𝐄𝐧𝐝𝐨𝐜𝐫𝐢𝐧𝐨𝐥𝐨𝐠𝐲 (1 product). 𝐎𝐩𝐡𝐭𝐡𝐚𝐥𝐦𝐨𝐥𝐨𝐠𝐲 (1 product). 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 (3 products). 𝐍𝐞𝐮𝐫𝐨𝐥𝐨𝐠𝐲 (3 products). 𝐈𝐦𝐦𝐮𝐧𝐨𝐝𝐞𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 (1 product). 𝐌𝐮𝐬𝐜𝐮𝐥𝐨𝐬𝐤𝐞𝐥𝐞𝐭𝐚𝐥 (1 product). 𝐃𝐞𝐫𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲 (3 products). 𝐀𝐞𝐬𝐭𝐡𝐞𝐭𝐢𝐜 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 (1 product). This diverse range of approved products underscores the expanding impact of CGT across various medical fields. 👉 34 approvals is certainly positive, however, our industry MUST address manufacturing challenges early in the development process to 𝐞𝐧𝐬𝐮𝐫𝐞 𝐭𝐡𝐞 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐯𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲 of these therapies. Thanks to Jason and Sanjay for recently speaking on this. 𝘞𝘩𝘢𝘵 𝘯𝘦𝘦𝘥𝘴 𝘵𝘰 𝘣𝘦 𝘢𝘥𝘥𝘦𝘥? Thanks again for allowing me to share this and hope you liked the red arrow contribution lol - Joanna Sadowska, PhD. P.S. - Want to stay ahead of the biotech revolution? Sign up for FREE to this week's 𝐂𝐆𝐓𝐰𝐞𝐞𝐤𝐥𝐲 newsletter and discover the latest breakthroughs and advancements, here: https://lnkd.in/etZK5kzZ #celltherapy #genetherapy #biotech #CGTweekly

7️⃣ Headlines from the last 7️⃣ days in Biotech ⤵ ⤵ ⤵ ▶ The UK has announced a $527M investment to enhance clinical trials, expand manufacturing capabilities, and support advanced medical research. This funding aims to drive innovation and improve healthcare outcomes. ▶ Johnson & Johnson has filed for FDA approval of a $6.5 billion autoimmune drug, setting up a competitive race with argenx and UCB. The move could reshape the market landscape for autoimmune treatments. ▶ Getinge has acquired organ transport specialist Paragonix Technologies, Inc. for $477M, marking its entry into the transplant market. The acquisition will enhance Getinge’s capabilities in organ preservation and transportation. ▶ Boston Scientific has received early European approval for its TAVR device, expediting the rollout of its advanced heart valve replacement technology. This approval boosts the company’s competitive edge in the European market. ▶ The FDA has approved Illumina's tumor biomarker test as a universal companion diagnostic, enabling precise genetic profiling across different cancer types. This approval supports personalized treatment strategies in oncology. ▶ Dexcom has introduced Stelo, its first over-the-counter glucose monitor, designed for easier blood sugar management without a prescription. This move aims to simplify access to diabetes care for a broader audience. ▶ Bayer has entered a $547M biobucks agreement with a biotech company focused on advancing noncoding RNA research. The deal aims to foster innovation in genetic therapies and explore new treatment possibilities. What else is new? Comment below ⤵ ⤵ ⤵

🔬 Exciting News: New Publication on Medrxiv 🌟 Peer review is ongoing, but I wanted to bring it to everyone's attention. 🎉 I'm thrilled to share our latest publication on Medrxiv! This study represents a significant advancement in our understanding of glioblastoma multiforme (GBM) treatment and its outcomes. 🧬 Background: Our research focused on the role of Aldehyde dehydrogenase-1A1 (ALDH1A1), a key enzyme in chemotherapy outcomes, particularly for the standard-of-care treatment, temozolomide, for GBM. Interestingly, we've found a correlation between high ALDH1A1 expression and poor prognosis across various cancers. 🤔 A pivotal discovery was the impact of Proton Pump Inhibitors (PPIs) – commonly prescribed for corticosteroid-induced gastrointestinal issues – as potential inducers of ALDH1A1, potentially affecting patient survival negatively. 📊 Methods: We delved into real-world data from 554 GBM patients, meticulously annotated from electronic medical records (EMR), as part of the XCELSIOR study. Our analysis, using a sophisticated time-varying Cox Proportional Hazard model, took into account various factors such as MGMT methylation status, patient demographics, and PPI use. 📈 Results: The data, spanning 225 cancer centers, revealed a noteworthy trend. Patients on PPIs generally showed a lower median overall survival (mOS) and 2-year survival rates. The effect was most pronounced in patients with MGMT-methylated GBM. 🚨 Conclusions: Our nationwide study strongly indicates the detrimental effects of PPIs on overall survival in GBM patients, especially those benefiting from SOC chemoradiotherapy. This raises critical concerns about the routine prescription of PPIs for managing chemotherapy-induced gastrointestinal toxicity. 🔑 Key Points: 🔑 Nationwide study signals potential risks of PPIs in GBM treatment. 🔑 Caution recommended in prescribing PPIs to GBM patients. 🔑 Prophylactic use of PPIs might elevate risk contrary to limiting chemo toxicity. 💡 Importance: This study sheds light on the unintended consequences of PPIs in GBM treatment, emphasizing the need for careful medication management. Our findings highlight the importance of re-evaluating standard practices to improve patient outcomes. 🔗 https://lnkd.in/gzQJdHJG #GBM #CancerResearch #MedicalPublication #ClinicalData #PatientCare #Medrxiv #HealthcareInnovation #Oncology #NeuroOncology

We’re closely observing new developments in the neuro space for early Alzheimer’s disease treatment. The launch of Leqembi highlights the intricate dynamics of pharmaceutical innovation and market strategy. 💡 Eisai's Ambitious Forecast: Despite initial challenges, Eisai’s revised projections for Leqembi are notable - aiming for nearly $2 billion in global revenues by 2026 and a potential leap to $8.8 billion by 2032. This underscores the significant market potential for effective Alzheimer's treatments. 🔍 Diagnostic Challenges: The key challenge for Leqembi lies in the diagnosis process - accurately identifying patients through amyloid testing. Eisai’s strategic investment in blood test technologies, like C2N Diagnostics, indicates a move towards more accessible and streamlined diagnostics. 🤝 Strategic Collaboration: Eisai’s plan to increase its neurology specialist team and enhance collaboration with Biogen reflects the importance of robust commercial strategies in pharma. It will be interesting to see how the market reacts after the stumble Biogen took with Aduhelm. 🚀 Future Directions: The focus on subcutaneous formulations and shifting to a primary care physician-centric model for Alzheimer’s care are strategic pivots that could significantly impact patient access and treatment adherence. At Healogix, we recognize these developments as pivotal for the future of Alzheimer's treatment. Our expertise in pharmaceutical market research positions us to deeply understand and analyze these trends, helping our clients navigate the complex landscape of neurology and beyond. #NeuroInnovation #PharmaMarketResearch #HealogixInsights

If you are a glioblastoma patient, especially those who are mgmt methylated, and are taking a ppi, show this to your doctor. PPIs are used to prevent or treat stomach problems and include. Here's a list of some commonly used proton pump inhibitors (PPIs): 1. Omeprazole 2. Lansoprazole 3. Esomeprazole 4. Pantoprazole 5. Rabeprazole 6. Dexlansoprazole

🚀 We are thrilled to announce the launch of Kidney Image Analysis Services via our cutting-edge NephroPath platform. Our AI-assisted image analysis services offer new and quantitative insights into renal pathology images, accelerating Chronic Kidney Disease (CKD) drug development studies. NephroPath’s AI-based quantification provides reproducible, consistent, and rapid scoring of renal pathology biomarkers. Compared to human assessments, it provides greater detail and precision. This can accelerate both preclinical and clinical development studies, as well as CKD biomarker discovery projects. For seamless implementation in ongoing projects, we provide comprehensive image analysis reports containing AI-based quantification findings, including biomarker scores and visual results. 🔗 Read the full story: https://lnkd.in/e8VRbDKz 🔍 Explore our kidney image analysis services: https://lnkd.in/eXtVwa6j #DigitalPathology #AIinPathology #KidneyHealth #DrugDevelopment